Committed to providing the highest quality of service to our clients, operating at the highest levels of integrity, and contributing to the betterment of mankind.
Dr. Suto joined Southern Research in August 2011. He and his team focus on basic research and target identification and lead discovery and optimization of new therapies for cancer, infectious diseases and neurological diseases and disorders.
He served as Vice President of Chemical and Pharmaceutical Sciences at Icagen Inc. from April 2004 until he joined Southern Research. From 2003 until 2004, Dr. Suto was Executive Vice President and Chief Scientific Officer of Neurion Pharmaceuticals, Inc., a California biotech company and from 1999 to 2002, Dr. Suto held senior management roles at DuPont Pharmaceuticals (acquired by Bristol-Myers Squibb Company) and Deltagen Research Laboratories, a subsidiary of Deltagen, Inc.
Prior to DuPont Pharmaceuticals, Dr. Suto held management positions at CombiChem, Inc. and Signal Pharmaceuticals, Inc. and from 1982-1993, held positions of increasing responsibility in the Chemistry Department at Parke-Davis Pharmaceutical Research in Ann Arbor, Michigan. Dr. Suto received his Ph.D. and his Bachelor's degree in Medicinal Chemistry from the State University of New York at Buffalo.
He is a member of the American Chemical Society and has served on the Editorial Boards for several scientific journals, including Combinatorial Chemistry and High Throughput Screening, Investigational Drugs Section Editor, Expert Opinion in Drug Discovery, and Expert Opinion on Therapeutic Patents. He currently holds 35 U.S. Patents, and has five additional U.S. Patents pending.